Neurocrine Biosciences, Inc. Stock News

Conference Call and Webcast Scheduled for Tuesday, October 28 SAN DIEGO , Oct. 7, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its third quarter 2025 financial results conference call and webcast for 1:30 p.m. Pacific Time (4:30 p.m.

SAN DIEGO , Oct. 6, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the appointment of Mike Sibley as Senior Vice President and General Manager of the company's Neuropsychiatry franchise. Sibley, a proven leader with more than 20 years of commercial experience in the biopharmaceutical industry, will be responsible for developing and executing the sales and marke...

Once-daily INGREZZA treatment was generally well tolerated and showed early and sustained improvements in chorea severity Findings presented at 2025 MDS International Congress of Parkinson's Disease and Movement Disorders®  SAN DIEGO , Oct. 6, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today presented new data from the open-label KINECT®-HD2 study demonstrating an establis...

The KINECT-PRO™ analysis is the first and only of its kind to report both remission of tardive dyskinesia symptoms and associated improvements in patient-reported outcomes. Post-hoc analysis from KINECT-PRO demonstrated substantial symptomatic remission rates at Week 24, even earlier than previous studies have reported.

SAN DIEGO , Sept. 22, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the presentation of new data from the Phase 2 SAVITRI™ study, which showed statistically significant and clinically meaningful improvement in depression severity at Day 28 and Day 56 with once-daily oral administration of 1 mg osavampator (NBI-1065845).

Neurocrine Biosciences, Inc. (NASDAQ:NBIX ) TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit September 17, 2025 12:40 PM EDT Company Participants Kyle Gano - CEO & Director Sanjay Keswani - Chief Medical Officer Todd Tushla Conference Call Participants Philip Nadeau - TD Cowen, Research Division Presentation Philip Nadeau TD Cowen, Research Division Good afternoon, an...

Additional Data from SAVITRI™ Study Expand on Top-Line Results Announced in April 2024 SAVITRI Poster Presentation Chosen as Finalist for Psych Congress Poster Awards SAN DIEGO , Sept. 16, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present new data from the Phase 2 SAVITRI study of osavampator in adults with major depressive disorder at Psych C...

Neurocrine Biosciences, Inc. (NASDAQ:NBIX ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 10:45 AM EDT Company Participants Kyle Gano - CEO & Director Sanjay Keswani - Chief Medical Officer Conference Call Participants Sean Laaman - Morgan Stanley, Research Division Presentation Sean Laaman Head of Healthcare Research & Equity Analyst Good morning, everyone, and welc...